By showing that waning immunity, and not the Delta variant, was the likely reason for the increase in breakthrough infections, the study suggests that it may not be necessary to reformulate a Pfizer-BioNTech booster that specifically targets this strain. For now, at least, a third injection identical to the first two would likely expand the vaccine’s initial record of protection against all variants, including Delta, Tartof noted.
–
